First-of-its-kind flu vaccine could be coming as FDA panel weighs historic shot

Moderna is seeking FDA approval for its new flu vaccine, mFlusiva, targeting individuals 50 and older. The FDA advisory committee meeting is a critical step toward a final decision before the winter flu season.